G

Genexine Inc
KOSDAQ:095700

Watchlist Manager
Genexine Inc
KOSDAQ:095700
Watchlist
Price: 4 980 KRW 2.26% Market Closed
Market Cap: ₩226.8B

Net Margin

-876.9%
Current
Improving
by 1 266.4%
vs 3-y average of -2 143.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-876.9%
=
Net Income
₩-38.1B
/
Revenue
₩4.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-876.9%
=
Net Income
₩-38.1B
/
Revenue
₩4.3B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Genexine Inc
KOSDAQ:095700
226.5B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 99% of companies in Korea
Percentile
1st
Based on 2 632 companies
1st percentile
-876.9%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Genexine Inc
Glance View

Market Cap
226.8B KRW
Industry
Biotechnology

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Intrinsic Value
1 202.9 KRW
Overvaluation 76%
Intrinsic Value
Price
G
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-876.9%
=
Net Income
₩-38.1B
/
Revenue
₩4.3B
What is Genexine Inc's current Net Margin?

The current Net Margin for Genexine Inc is -876.9%, which is above its 3-year median of -2 143.4%.

How has Net Margin changed over time?

Over the last 3 years, Genexine Inc’s Net Margin has decreased from -317.8% to -876.9%. During this period, it reached a low of -6 027.3% on Mar 31, 2025 and a high of -317.8% on Aug 30, 2022.

Back to Top